This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-Î± (IFN-Î±) and thymosin Î±1 (TÎ±1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-Î±2b therapy, and in four interferon naive patients. These fifteen hepatitis B surface antigen (HBsAg) positive and serum hepatitis B virus (HBV) DNA positive patients were given TÎ±1 (1 mg) subcutaneously (sc) on 4 consecutive days. Low-dose lymphoblastoid IFN-Î± (3 MU) was administered intramuscularly (IM) on the fourth day. Beginning with the second and for the subsequent 25 weeks, patients self-administered TÎ±1 twice weekly in the morning followed, 12 h later, by 3 million units (MU) lymphoblastoid IFN-Î±. Patients were followed-up for 12 months. Nine (60%) of the 15 patients, including six (55%) of the 11 patients previously treated with IFN-Î±2b, responded by losing serum HBV DNA and normalizing alanine aminotransferase (ALT) values. Six of the nine responders seroconverted to HBsAg negativity. Significant improvements in the Knodell histological activity index were observed in the responders and no significant adverse effects were observed. Combination low-dose lymphoblastoid IFN-Î± and TÎ±1 treatment may provide a safe and potentially effective therapeutic approach in chronic hepatitis B. These results require confirmation in future randomized controlled studies. Â© 1996 Blackwell Science Ltd.
Rasi, G., Mutchnick, M.G., Di Virgilio, D., Sinibaldi Vallebona, P., Pierimarchi, P., Colella, F., et al. (1996). Combination low-dose lymphoblastoid interferon and thymosin Î±1 therapy in the treatment of chronic hepatitis B. JOURNAL OF VIRAL HEPATITIS, 3(4), 191-196.
|Tipologia:||Articolo su rivista|
|Citazione:||Rasi, G., Mutchnick, M.G., Di Virgilio, D., Sinibaldi Vallebona, P., Pierimarchi, P., Colella, F., et al. (1996). Combination low-dose lymphoblastoid interferon and thymosin Î±1 therapy in the treatment of chronic hepatitis B. JOURNAL OF VIRAL HEPATITIS, 3(4), 191-196.|
|IF:||Con Impact Factor ISI|
|Settore Scientifico Disciplinare:||Settore MED/07 - Microbiologia e Microbiologia Clinica|
|Revisione (peer review):||Sì, ma tipo non specificato|
|Stato di pubblicazione:||Pubblicato|
|Data di pubblicazione:||1996|
|Titolo:||Combination low-dose lymphoblastoid interferon and thymosin Î±1 therapy in the treatment of chronic hepatitis B|
|Autori:||Rasi, G; Mutchnick, MG; Di Virgilio, D; Sinibaldi Vallebona, P; Pierimarchi, P; Colella, F; Favalli, C; Garaci, E|
|Appare nelle tipologie:||01 - Articolo su rivista|